Your session is about to expire
← Back to Search
Beta Blocker
Beta Blocker ABAB Sequence for Heart Failure
Phase 4
Waitlist Available
Led By Parag Goyal, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the maximum amount of time a subject could have been assessed for this outcome measure is 6 times across 36 weeks. this outcome was measured at each end of period visit (weeks 6, 12, 18, 24, 30) and at the end of intervention (weeks 12, 18, 24, 30, or 36)
Awards & highlights
Study Summary
This trial will test whether it is feasible to stop taking beta-blockers for patients with Heart Failure with Preserved Ejection Fraction. 16 patients will each do 4 periods of taking/not taking the medication, and then be interviewed about feasibility and practicality.
Eligible Conditions
- Diastolic Heart Failure
- Heart Failure
- Cardiovascular Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ the maximum amount of time a subject could have been assessed for this outcome measure is 6 times across 36 weeks. this outcome was measured at each end of period visit (weeks 6, 12, 18, 24, 30) and at the end of intervention (weeks 12, 18, 24, 30, or 36)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the maximum amount of time a subject could have been assessed for this outcome measure is 6 times across 36 weeks. this outcome was measured at each end of period visit (weeks 6, 12, 18, 24, 30) and at the end of intervention (weeks 12, 18, 24, 30, or 36)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative Interview
Trial Design
2Treatment groups
Active Control
Group I: Beta Blocker ABAB SequenceActive Control1 Intervention
This arm will follow an ABAB sequence. "A" representing ON beta blockers and "B" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.
Group II: Beta Blocker BABA SequenceActive Control1 Intervention
This arm will follow a BABA sequence. "A" representing ON beta blockers and "B" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,054 Previous Clinical Trials
1,316,519 Total Patients Enrolled
9 Trials studying Heart Failure
222,852 Patients Enrolled for Heart Failure
National Institute on Aging (NIA)NIH
1,669 Previous Clinical Trials
28,005,105 Total Patients Enrolled
42 Trials studying Heart Failure
213,306 Patients Enrolled for Heart Failure
Parag Goyal, MDPrincipal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
9 Total Patients Enrolled
1 Trials studying Heart Failure
9 Patients Enrolled for Heart Failure
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has the FDA sanctioned Beta Blocker BABA Sequence for public consumption?
"Beta Blocker BABA Sequence has already been authorized and is thus rated a 3 on the safety scale. This indicates that the treatment can be considered safe since it is currently in Phase 4 trials."
Answered by AI
Is this research currently recruiting participants?
"At present, this medical trial is looking for patients. As recorded on clinicaltrials.gov, the study was first published on April 1st 2021 and modified as recently as June 24th 2022."
Answered by AI
What is the aggregate figure of individuals engaging in this experiment?
"Affirmative. Clinicaltrials.gov data indicates that this study, which was first posted on April 1st 2021, is actively recruiting participants. The researchers require 16 individuals from one medical centre to join the trial."
Answered by AI
What medical conditions can be addressed with the Beta Blocker BABA Sequence?
"Beta-blocker BABA Sequence is a common course of care for treating hypesthesia. It has also been employed in the management of diseases such as increased intra ocular pressure (IOP), tachycardia, ventricular arrhythmia, and angina pectoris."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger